Skip to content
Strategic Partnering
News
Contact Us
Menu
Strategic Partnering
News
Contact Us
Invest
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
BirchBioMed Welcomes Dr. Carlos Roberto Camozzi as Chief Medical Officer
2023-04-03-BirchBioMed-DrCarlosCamozziappt
